<DOC>
	<DOCNO>NCT01975324</DOCNO>
	<brief_summary>Determine whether dalfampridine ( Ampyra ) improve visual function patient nonarteritic ischemic optic neuropathy ( NAION ) stable visual impairment .</brief_summary>
	<brief_title>A New Medicine Treat Nonarteritic Anterior Ischemic Optic Neuropathy ( NAION )</brief_title>
	<detailed_description>The aim study determine whether dalfampridine improve visual function patient nonarteritic ischemic optic neuropathy ( NAION ) stable visual impairment . The objective double mask crossover study determine whether visual function improve numerous parameter . This include high contrast visual acuity , low contrast visual acuity , visual field , visual quality life ( VFQ-39 ) , electrophysiology , multi focal electro retinography ( mERG ) , visual evoke potential ( VEP ) , structure , spectral domain optical coherence tomography ( OCT ) . Based promising result use dalfampridine Multiple Sclerosis ( MS ) stroke , hypothesize patient chronic stable deficit nonarteritic ischemic optic neuropathy ( NAION ) improve visual function administration dalfampridine .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy , Ischemic</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>NAION 6 month prior enrollment visual acuity 20/40 bad Current use Dalfampridine ( Ampyra ) Pregnancy History seizures Renal Failure Not able perform test</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Ampyra</keyword>
	<keyword>NAION</keyword>
	<keyword>Dalfampridine</keyword>
</DOC>